Related Experiment Video

Updated: Aug 18, 2026

Yeast As a Chassis for Developing Functional Assays to Study Human P53
14:57

Yeast As a Chassis for Developing Functional Assays to Study Human P53

Published on: August 4, 2019

Prospective therapeutic applications of p53 inhibitors

Andrei V Gudkov1, Elena A Komarova

  • 1Department of Molecular Genetics, Lerner Research Institute, The Cleveland Clinic Foundation, Cleveland, OH 44195, USA. gudkov@ccf.org

Biochemical and Biophysical Research Communications
|May 4, 2005
PubMed

Insights

The tumor suppressor p53 protein can cause side effects during cancer therapy. Inhibiting p53 may protect normal tissues, but also offers new ways to sensitize tumors to treatment.

Area of Science:

  • Molecular Biology
  • Cancer Research
  • Pharmacology

Background:

  • The p53 protein is crucial for cancer prevention but also contributes to side effects in normal tissues during cancer treatment.
  • p53's role in inducing apoptosis (programmed cell death) can lead to excessive cell death in healthy tissues.
  • p53 also has protective functions, such as inducing growth arrest and preventing mitotic catastrophe.

Purpose of the Study:

  • To explore the dual role of p53 in cancer therapy.
  • To investigate the potential of p53 inhibitory strategies for both protecting normal tissues and enhancing anti-cancer treatments.
  • To highlight the need for targeted pharmacological agents that can modulate specific p53 functions.

Main Methods:

  • Review of p53's known functions in normal tissues and tumors.
  • Discussion of p53 inhibitory strategies and their validation using pifithrin-alpha.
  • Analysis of the implications of inhibiting different p53 functions.

Main Results:

  • p53 inhibition can protect normal tissues from chemotherapy and radiotherapy side effects.
  • p53's growth-arresting function, when inhibited, can sensitize tumor cells to treatment.
  • pifithrin-alpha demonstrated broad tissue-protecting capacity.

Conclusions:

  • Targeting p53 offers a dual therapeutic strategy in cancer treatment.
  • Selective inhibition of p53's pro-apoptotic function may protect normal tissues.
  • Inhibiting p53's growth arrest function could enhance tumor cell sensitivity to therapy, necessitating the development of specific pharmacological agents.

More Related Videos

Functionalized Spirocyclic Heterocycle Synthesis and Cytotoxicity Assay05:17

Functionalized Spirocyclic Heterocycle Synthesis and Cytotoxicity Assay

Published on: February 9, 2021

Detection of Aggregation-Prone Behavior in Mutant P53 V157F Breast Cancer Cells Using Multipoint Thioflavin T Fluorescence04:56

Detection of Aggregation-Prone Behavior in Mutant P53 V157F Breast Cancer Cells Using Multipoint Thioflavin T Fluorescence

Published on: December 30, 2025

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
DNA Damage can Stall the Cell Cycle02:36

DNA Damage can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
DNA Damage Can Stall the Cell Cycle02:36

DNA Damage Can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...